Evidence map›Paper›PMID 35982837›Full record

ArticleCritical care explorations2022

Point-of-Care Lung Ultrasound Predicts Severe Disease and Death Due to COVID-19: A Prospective Cohort Study.

Paul W Blair, Trishul Siddharthan, Gigi Liu, Jiawei Bai, Erja Cui, Joshua East, Phabiola Herrera, Lalaine Anova, Varun Mahadevan, Jimin Hwang and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Critical care explorations, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Observational
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 3 institutions in 1 country.

Paul W BlairAustere environments Consortium for Enhanced Sepsis Outcomes, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD.
Trishul SiddharthanDivision of Pulmonary and Critical Care Medicine, University of Miami, Miami, FL.
Gigi LiuDivision of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Jiawei BaiDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Erja CuiDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Joshua EastDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Phabiola HerreraDivision of Pulmonary and Critical Care Medicine, University of Miami, Miami, FL.
Lalaine AnovaAustere environments Consortium for Enhanced Sepsis Outcomes, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD.
Varun MahadevanDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Jimin HwangDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Shakir HossenDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Stefanie SeoDepartment of Emergency Medicine, Johns Hopkins University, Baltimore, MD.
Olamide SonugaDepartment of Emergency Medicine, Johns Hopkins University, Baltimore, MD.
Joshua LawrenceDepartment of Emergency Medicine, Johns Hopkins University, Baltimore, MD.
Jillian PetersDivision of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Andrea L CoxDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD.
Yukari C ManabeDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD.
Katherine FenstermacherDepartment of Emergency Medicine, Johns Hopkins University, Baltimore, MD.
Sophia SheaDepartment of Emergency Medicine, Johns Hopkins University, Baltimore, MD.
Richard E RothmanDepartment of Emergency Medicine, Johns Hopkins University, Baltimore, MD.
Bhakti HansotiDepartment of Emergency Medicine, Johns Hopkins University, Baltimore, MD.
Lauren SauerDepartment of Emergency Medicine, Johns Hopkins University, Baltimore, MD.
Ciprian CrainiceanuDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Danielle V ClarkAustere environments Consortium for Enhanced Sepsis Outcomes, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD.
Johns Hopkins University · USJohns Hopkins Medicine · USUniversity of Miami · US

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
6 · The paper itself

Abstract

The clinical utility of point-of-care lung ultrasound (LUS) among hospitalized patients with COVID-19 is unclear.

designProspective cohort study.

settingA large tertiary care center in Maryland, between April 2020 and September 2021. PATIENTS: Hospitalized adults (≥ 18 yr old) with positive severe acute respiratory syndrome coronavirus 2 reverse transcriptase-polymerase chain reaction results.

interventionsNone. MEASUREMENTS AND MAIN

resultsAll patients were scanned using a standardized protocol including 12 lung zones and followed to determine clinical outcomes until hospital discharge and vital status at 28 days. Ultrasounds were independently reviewed for lung and pleural line artifacts and abnormalities, and the mean LUS Score (mLUSS) (ranging from 0 to 3) across lung zones was determined. The primary outcome was time to ICU-level care, defined as high-flow oxygen, noninvasive, or invasive mechanical ventilation, within 28 days of the initial ultrasound. Cox proportional hazards regression models adjusted for age and sex were fit for mLUSS and each ultrasound covariate. A total of 264 participants were enrolled in the study; the median age was 61 years and 114 participants (43.2%) were female. The median mLUSS was 1.0 (interquartile range, 0.5-1.3). Following enrollment, 27 participants (10.0%) went on to require ICU-level care, and 14 (5.3%) subsequently died by 28 days. Each increase in mLUSS at enrollment was associated with disease progression to ICU-level care (adjusted hazard ratio [aHR], 3.61; 95% CI, 1.27-10.2) and 28-day mortality (aHR, 3.10; 95% CI, 1.29-7.50). Pleural line abnormalities were independently associated with disease progression to death (aHR, 20.93; CI, 3.33-131.30).

conclusionsParticipants with a mLUSS greater than or equal to 1 or pleural line changes on LUS had an increased likelihood of subsequent requirement of high-flow oxygen or greater. LUS is a promising tool for assessing risk of COVID-19 progression at the bedside.

Indexed as

cohort studiesCOVID-19severe acute respiratory syndrome coronavirus 2survival analysisultrasonography

Identifiers

PMID35982837
PMCPMC9377680
OpenAlexW4290878983

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.